-
公开(公告)号:US20220273713A1
公开(公告)日:2022-09-01
申请号:US17622563
申请日:2020-06-26
申请人: The University of Melbourne , Olivia Newton-John Cancer Research Institute , CSL INNOVATION PTY LTD
发明人: Andreas BEHREN , Jonathan CEBON , Marc Rigau CORTAL , Thomas Samuel FULFORD , Dale Ian GODFREY , Andrew HAMMET , Simone OSTROUSKA , Con PANOUSIS , Adam Peter ULDRICH
摘要: The present disclosure relates to methods for inhibiting activation of γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject as well as methods for inducing or enhancing γδ T cells that express a Vγ9+ TCR in a subject by administering a BTN2A1 antagonist to a subject. The disclosure additionally relates to BTN2A1 antagonists and BTN2A1 agonists.
-
公开(公告)号:US20220228222A1
公开(公告)日:2022-07-21
申请号:US17609517
申请日:2020-05-08
申请人: Christopher Goodnow , Megan Barnet , Katherine Jackson , Jonathan Cebon , Andreas Behren , Garvan Institute of Medical Research , Olivia Newton-John Cancer Research Institute
IPC分类号: C12Q1/6886 , A61P35/04 , C07K16/28 , C07K16/18 , A61P35/00
摘要: The present disclosure relates to predicting a patient's response to cancer therapy based on the presence or absence of loss of function NOD-2 variants, as well as methods of treating cancer comprising inhibiting NOD-2 function.
-
公开(公告)号:US20210324035A1
公开(公告)日:2021-10-21
申请号:US17273192
申请日:2019-09-04
申请人: The Regents of the University of California , California Institute of Technology , The Olivia Newton-John Cancer Research Institute
发明人: Owen N. Witte , Jami McLaughlin Witte , Antoni Ribas , Lili Yang , Michael T. Bethune , Jonathan Cebon , Katherine Woods , Ashley J. Knights , David Baltimore
IPC分类号: C07K14/725 , A61K35/17 , C12N15/86 , C12N5/0783 , A61P35/00
摘要: Tumor-specific T cell receptor (TCR) gene transfer enables specific and potent immune targeting of tumor antigens. The canonical cancer-testis antigen, NY-ESO-1, is not expressed in normal tissues but is aberrantly expressed across a broad array of cancer types. It has also been targeted with A2-restricted TCR gene therapy without adverse events or notable side effects. To enable the targeting of NY-ESO-1 in a broader array of HLA haplotypes, we isolated TCRs specific for NY-ESO-1 epitopes presented by four MHC molecules: HLA-A2, -B07, -B18, and -C03. Using these TCRs, we have developed an approach to extend TCR gene therapies targeting NY-ESO-1 to patient populations beyond those expressing HLA-A2.
-
公开(公告)号:US20190105405A1
公开(公告)日:2019-04-11
申请号:US16028130
申请日:2018-07-05
申请人: Beate Lackmann , Monash University , Memorial Sloan-Kettering Cancer Centre , Ludwig Institute for Cancer Research Ltd. , Olivia Newton-John Cancer Research Institute
发明人: Martin Lackmann , Peter W. Janes , Lakmali Atapattu Mudiyanselage , Andrew M. Scott , Dimitar B. Nikolov , Nayanendu Saha
摘要: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
-
公开(公告)号:US20220169747A1
公开(公告)日:2022-06-02
申请号:US17442072
申请日:2020-03-20
发明人: Andrew Mark SCOTT , Hui Kong GAN , Zhanqi LIU , Sagun PARAKH
IPC分类号: C07K16/32 , G01N33/574
摘要: The present disclosure is directed to binding proteins to the extracellular domain (ECD) of HER2/ErbB2. More particularly, the binding proteins bind to a conformational epitope which is exposed in cells in response to HER2 amplification or activation.
-
公开(公告)号:US11160873B2
公开(公告)日:2021-11-02
申请号:US16028130
申请日:2018-07-05
申请人: Monash University , Memorial Sloan-Kettering Cancer Centre , Ludwig Institute for Cancer Research Ltd. , Olivia Newton-John Cancer Research Institute , Beate Lackmann
发明人: Martin Lackmann , Peter W. Janes , Lakmali Atapattu Mudiyanselage , Andrew M. Scott , Dimitar B. Nikolov , Nayanendu Saha
IPC分类号: G01N33/53 , C07K16/18 , A61K39/395 , A61K47/68 , C07K16/40 , C07K16/30 , A61P35/00 , C07K16/28 , A61K39/00
摘要: Expression of proteolytically active, high molecular weight ADAM10 protease is relatively increased in tumour cells that also express the putative tumour stem cell marker CD133. A recombinant humanized antibody or antibody fragment based on 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumour cells and also as a therapeutic agent for treating cancers, tumours and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumour, renal tumour, prostate cancer, sarcoma and/or melanoma.
-
-
-
-
-